earnings callInteresting earnings call transcript at seeking alpha. Excerpts pasted in below. I like this company. They dont seem to be BS artists releasing a lot of BS PRs. As seen in the excerpts they have an interesting pipeline. Droxidopa is already well established to be safe, so if they can expand the label to fibromyalgia or ADHD, thats HUGE. The scientists they have conducting the trials are top notch. As for the NOH study, read the transcript and you'll appreciate the complexities of choosing an endpoint and how many equally good endpoints there are. Encouraging that they worked with the FDA for the 302 study to determine the endpoint, so it might be easier to convince the FDA that additional paramaters should be considered.
"In addition to potentially treating fibromyalgia, there has been significant interest in better understanding the potential benefit of Droxidopa for the treatment of adult attention deficit hyperactivity disorder or ADHD. ...We have been working closely with the investigator for this study, Dr. Adler in New York to facilitate an exploratory Phase II trial. This will be a single-center, 12-week study conducted under physician sponsored I&D, and is intended to evaluate 20 adult ADHD patients. ...the study is expected to be under way in the next few weeks, and should likely yield data in the second quarter of 2010. We are very pleased to be working with Dr. Adler on this study.
As have been the case for most of the year, it was CH-4051 that continues to generate the greatest buzz amongst physicians and potential partners at the conference. We believe the CH-4051 has tremendous promise as a treatment for rheumatoid arthritis supported by a robust body of pre-clinical data suggesting proven inhibition of the enzyme dihydroorotate reductase, and Phase I data demonstrating its impressive safety and tolerability at levels believed to exceed likely therapeutic dosages. We are all excited to see what was CH-4051 can do in the Phase II trail."